Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

10.36 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stay informed with the top movers within the S&P500 index on Thursday.
Let's delve into the developments on the US markets one hour before the close of the markets on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
Viatris (NASDAQ:VTRS) Beats Q2 Sales Targets, Stock Soars
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The company expects the full year’s... 
Via StockStory
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Viatris (VTRS) Reports Earnings Tomorrow: What To Expect
Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, contributory, and induced infringement claims. 
Via Benzinga
Topics Intellectual Property
1 Mid-Cap Stock on Our Buy List and 2 We Avoid
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
What's going on in today's session: S&P500 movers
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy. 
Via Benzinga
Top S&P500 movers in Friday's session
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Why Viatris (VTRS) Stock Is Falling Today
Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for blepharitis, an inflammatory condition of the eyelids, failed to meet the main... 
Via StockStory
What's going on in today's session: S&P500 gap up and gap down stocks
Stay updated with the S&P500 gap up and gap down stocks on Friday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 S&P 500 Stocks in Hot Water
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
Viatris Eye Drops Data Shows Promise For Blurred Near Vision
Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits. 
Via Benzinga
3 Unprofitable Stocks with Mounting Challenges
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
3 Healthcare Stocks with Questionable Fundamentals
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
VTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost Review
Medication company Viatris (NASDAQ:VTRS) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. Its non-GAAP EPS of $0.50 per share was 2.3%... 
Via StockStory
Topics Economy World Trade
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook. 
Via Benzinga
Viatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS
From Pomerantz LLP
Via GlobeNewswire
VIATRIS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
From Kahn Swick & Foti, LLC
Via Business Wire
Deadline Soon: Viatris Inc. (VTRS) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
SHAREHOLDER REMINDER: Berger Montague Reminds Viatris (NASDAQ: VTRS) Investors of the June 3, 2025 Deadline
From Berger Montague
Via GlobeNewswire
VTRS DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important June 3 Deadline in Securities Class Action – VTRS
From The Rosen Law Firm PA
Via GlobeNewswire
VIATRIS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
From SkyMedia, LLC
Via GlobeNewswire
VTRS Investors Have the Opportunity to Lead the Viatris Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.